Smith & Nephew is a global medical technology company that designs and manufactures medical devices and advanced wound care solutions. The company focuses on restoring health, mobility, and confidence through its portfolio of products. Its business segments include medical devices and advanced wound care, serving customers in the healthcare sector. The company operates globally, providing technologies that address various medical needs.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Devices Homepage smith-nephew.com
Sector Healthcare IR page smith-nephew.com/en/who-we-are/investors
Tags
medical devices, wound care, surgical instruments, orthopedics, cardiovascular, urology, aesthetic medicine, healthcare technology
Press page smith-nephew.com/en/news

Metrics

Valuation  
Market cap $ 11.685B
Market cap (USD) $ 11.685B
P/E 18.83
PEG 0.46
P/BV 2.26
P/S 1.90
P/OCF 9.09
P/FCF 13.71
Dividend yield 0.04%
Turnover / mcap —
Returns  
ROE 11.8%
ROI 7.4%
ROIC 7.6%
Profit margin 10.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 41.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) —
Debt/Equity 58.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 66
Quality score 47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2014 FY 2011 FY 2010 FY 2009
Revenue 6.164B 5.81B 5.549B 5.215B 5.212B 4.56B 5.138B 4.904B 4.765B 4.669B 0 4.27K 3.962K 3.772K
Net profit 625M 412M 263M 223M 524M 448M 600M 663M 767M 784M — — — —
Free cash flow 852M 606M 181M 110M 469M — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2014 FY 2011 FY 2010 FY 2009
Share price 32.81 24.58 27.28 26.89 34.62 42.17 48.07 37.38 35.01 30.08 — 52.54 52.54 51.18
Price performance 12m 0.33 -0.1 0.01 -0.22 -0.18 -0.12 0.29 0.07 0.16 -0.16 — 0 0.03 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (USD) 230M 223M 246M 292M 307M 356M 345M 339M 289M 296M
↳ 5y CAGR +1,589.7% +6.7% +9.1% +9.1% +6.6% -0.2% -0.7%
Reported Mar 5, 2018 Mar 5, 2018 Mar 4, 2019 Mar 2, 2020 Mar 1, 2021 Mar 7, 2022 Mar 6, 2023 Mar 11, 2024 Mar 10, 2025 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Smith & Nephew plc SPON ADR American Depositary Shares (ADS)

Identification code

ISIN: US83175M2052

Nature of the transaction

Director and PDMRs are participants of the Company's Employee Stock Purchase Plan, which purchased American Depository Shares through the Company's Dividend Re-Investment Plan following the 2026 interim dividend payment on 6 November 2026.

This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Smith & Nephew plc ordinary shares of USD 0.20 each

Identification code

ISIN: GB0009223206

Nature of the transaction

Purchase of ordinary shares through the Company’s Dividend Re-Investment Plan following the 2026 interim dividend payment on 6 November 2026.

Item 1. Press release entitled “Smith+Nephew Third Quarter 2026 Trading Report”, dated November 4, 2026.

Strong Sports Medicine momentum continues; full-year guidance revised to reflect slower growth than expected in Orthopaedics

Smith+Nephew (LSE:SN, NYSE:SNN) trading update for the quarter ended 26 September 2026.

Q3 Highlights ● Q3 revenue of $1,551 million (Q3 2025: $1,501 million), representing 3.4% revenue growth on both an underlying and reported basis (Q3: 63 trading days, in line with Q3 2025): o Strong Sports Medicine & ENT performance, including double-digit growth in Sports Medicine Joint Repair o Improved performance in Advanced Wound Management, led by acceleration in Devices o Orthopaedics returned to growth, despite soft market conditions and continued weak performance in US Hips and Knees o Double-digit growth in CATALYSTEM™, CONCELOC™, AETOS™, CORI™, REGENETEN™, Q-FIX™, FASTSEAL™, LEAF™ and PICO™ ● Cementless LANDMARK™ Knee received 510(k) clearance, with first US surgical cases completed ● Completed first cases using TESSA™ Spatial Surgery System for femoral repair of the ACL, and submitted for regulatory approval for use in tibial tunnel placement

Full year

Prompts

Smith & Nephew SNATS, Inc. (ticker SNN), listed in United States.

Company History

Date Change Detail
Mar 15, 2019 Acquired Acquired Osiris Therapeutics, Inc. (CIK 1360886). Its filings from before the deal are on its own company page, not shown here.
May 2, 2014 Acquired Acquired Arthrocare Corp (CIK 1005010). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Smith & Nephew SNATS, Inc.

ETF Weight in ETF Shares Market value As of
BINV 1.51% 256,404 $ 7.387M Jun 30, 2026
TIIV 1.02% 10,644 $ 335.925K Jul 31, 2026
ALRG 0.62% 1,638 $ 51.695K Jul 31, 2026
APIE 0.23% 90,932 $ 2.615M Aug 31, 2026
AVSD 0.11% 13,467 $ 417.073K Nov 16, 2026
JSTC 0.06% 5,964 $ 184.705K Nov 17, 2026
DFIC 0.06% 297,661 $ 9.227M Nov 12, 2026
DFAX 0.05% 181,094 $ 5.614M Nov 12, 2026
AVDE 0.04% 277,631 $ 8.598M Nov 16, 2026
DFSI 0.04% 14,405 $ 446.555K Nov 12, 2026
DXIV 0.01% 788 $ 24.428K Nov 12, 2026